All News

FDA approval brings durvalumab plus BCG to frontline high-risk NMIBC, boosting disease-free survival and expanding oncology options.

Pharmacists play a big role in biomarker testing, patient selection, and counseling on immune checkpoint inhibitor therapy in endometrial cancer.

The ability to anticipate access delays, navigate benefit changes, and protect continuity of care has become a defining role of modern pharmacy practice.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what the pharmacist's role in MS supplement safety.

Amid the evolving landscape of MS treatments, there is an increasing emphasis on strategic approaches to early intervention and switching therapies.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what works and what doesn't in MS supplements.

ENHANCE trial data show ublituximab-xiiy can start with a single bioequivalent infusion, easing multiple sclerosis treatment initiation.

Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.

Phase 3 UTOPIA trial shows UGN-103 intravesical mitomycin after TURBT achieves 78% complete response with favorable safety.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic presenting on management of High-risk multiple sclerosis patients, discussed safety, treatment, and emerging strategies.

ASCO pooled phase 3 data show that pirtobrutinib in treatment‑naive CLL/SLL delivers 93% responses, durable control, and low cardiac risk.

Erin Zacholski, PharmD, BCOP, discusses the critical role of biomarker testing, immune checkpoint inhibitor selection, and pharmacist-led patient counseling in recurrent and metastatic endometrial cancer management.

New household data show recent COVID-19 shots cut at-home spread by 43%, strengthening pharmacist counseling on staying up to date.

Tim Casey addresses what this means for health care providers and pharmacists, and why this may represent a rare window for meaningful, bipartisan reform.

Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.

Craig Beavers highlights 3 major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.

Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.

Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.

Clinical pharmacists may play an increasingly important role in longitudinal metabolic care, medication optimization, patient education, and multidisciplinary peptide management.

Spencer Durham, PharmD, FCCP, BCPS, BCIDP, discusses why hepatitis B remains an active public health threat.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.

Community pharmacists emerged as the critical clinical link in the modern patient care continuum

This week's episode covers the White House's expansion of the TrumpRx.gov platform, the pharmacist's critical role in closing adult hepatitis B vaccination gaps, and new FDA approvals in immunology, oncology, and cardiovascular care.